Bioterrorism for the respiratory physician

Respirology

Volumn 14, Issue 1, 2009, Pages 5-11

  Waterer, Grant W ^a,b   Robertson, Hannah ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Anthrax; Bioterrorism; Plague; Tularaemia

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; RICIN; RIFAMPICIN; STAPHYLOCOCCUS ENTEROTOXIN B; STREPTOMYCIN; VACCINE; VANCOMYCIN;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG SAFETY; HISTORY OF MEDICINE; HOSPITAL PHYSICIAN; HUMAN; LABORATORY TEST; LUNG DISEASE; MEDICAL SOCIETY; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TULAREMIA;

EID: 58149123009     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01446.x     Document Type: Review

References (56)

1. Cernenko EV, Mcbride A, Gorelik MB. The Scythians 700-300BC. Osprey Publishing, Oxford, 1983.
2. Center for Disease Control and Prevention (CDC). 2008. Bioterrorism agents/diseases Accessed 1 June 2008.] Available from URL: http://www.bt.cdc. gov/agent/agentlist-category.asp.
3. The Office of the Public Health Service Historian. 2004. A brief history of anthrax. U.S. National Library of Medicine Accessed 1 June 2008.] Available from URL: http://lhncbc.nlm.nih.gov/apdb/phsHistory/resources/anthrax/ anthrax_text.html.
4. Willis EA. Landscape with dead sheep: what they did to Gruinard island. Med. Confl. Surviv. 2002 18 : 199 210.
5. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994 266 : 1202 8.
6. Brookmeyer R, Blades N, Hugh-Jones M, Henderson DA. The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. Biostatistics 2001 2 : 233 47.
7. Zilinskas RA. Iraq's biological weapons. The past as future? JAMA 1997 278 : 418 24.
8. Enserink M, Bhattacharjee Y. Bioterrorism. Scientists seek answers, ponder future after anthrax case suicide. Science 2008 321 : 754 5.
9. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 2001 7 : 933 44.
10. Kyriacou DN, Stein AC, Yarnold PR, Courtney DM, Nelson RR et al. Clinical predictors of bioterrorism-related inhalational anthrax. Lancet 2004 364 : 449 52.
11. Ketai L, Alrahji AA, Hart B, Enria D, Mettler F et al. Radiologic manifestations of potential bioterrorist agents of infection. AJR Am. J. Roentgenol. 2003 180 : 565 75.
12. Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J et al. Bichat guidelines for the clinical management of anthrax and bioterrorism-related anthrax. Euro Surveill. 2004 9 : E3 4.
13. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg. Infect. Dis. 2008 14 : pii : 07 0969.
14. Centers for Disease Control and Prevention. Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. JAMA 2001 286 : 2536 7.
15. Sato PA, Reed RJ, Smith TC, Wang L. Monitoring anthrax vaccine safety in US military service members on active duty: surveillance of 1998 hospitalizations in temporal association with anthrax immunization. Vaccine 2002 20 : 2369 74.
16. Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH et al. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol. Drug Saf. 2004 13 : 825 40.
17. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002 287 : 2236 52.
18. Wheelis M. Biological warfare at the 1346 siege of Caffa. Emerg. Infect. Dis. 2002 8 : 971 5.
19. Jacobs MK. The history of biologic warfare and bioterrorism. Dermatol. Clin. 2004 22 : 231 46, v.
20. Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin. Infect. Dis. 2005 40 : 1166 72.
21. Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J et al. Bichat guidelines for the clinical management of plague and bioterrorism-related plague. Euro Surveill. 2004 9 : E5 6.
22. Costello C, Moldenhauer J. Applying rapid microbiology techniques in the war against bioterrorism. PDA J. Pharm. Sci. Technol. 2004 58 : 279 83.
23. Rotz LD, Hughes JM. Advances in detecting and responding to threats from bioterrorism and emerging infectious disease. Nat. Med. 2004 10 (Suppl. 12 S130 6.
24. Chanteau S, Rahalison L, Ralafiarisoa L, Foulon J, Ratsitorahina M et al. Development and testing of a rapid diagnostic test for bubonic and pneumonic plague. Lancet 2003 361 : 211 16.
25. Loiez C, Herwegh S, Wallet F, Armand S, Guinet F et al. Detection of Yersinia pestis in sputum by real-time PCR. J. Clin. Microbiol. 2003 41 : 4873 5.
26. Splettstoesser WD, Rahalison L, Grunow R, Neubauer H, Chanteau S. Evaluation of a standardized F1 capsular antigen capture ELISA test kit for the rapid diagnosis of plague. FEMS Immunol. Med. Microbiol. 2004 41 : 149 55.
27. Tomaso H, Thullier P, Seibold E, Guglielmo V, Buckendahl A et al. Comparison of hand-held test kits, immunofluorescence microscopy, enzyme-linked immunosorbent assay, and flow cytometric analysis for rapid presumptive identification of Yersinia pestis. J. Clin. Microbiol. 2007 45 : 3404 7.
28. Centres for Disease Control and Prevention. 2005. Plague Medical Management Training Module Accessed 1 June 2008.] Available from URL: http://www.bt.cdc.gov/agent/plague/trainingmodule/5/01.asp.
29. Welch TJ, Fricke WF, McDermott PF, White DG, Rosso ML et al. Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS ONE. 2007 2 : e309.
30. Davis CJ. Nuclear blindness: an overview of the biological weapons programs of the former Soviet Union and Iraq. Emerg. Infect. Dis. 1999 5 : 509 12.
31. Smiley ST. Current challenges in the development of vaccines for pneumonic plague. Expert Rev. Vaccines 2008 7 : 209 21.
32. Ales NC, Katial RK. Vaccines against biologic agents: uses and developments. Respir. Care Clin. N. Am. 2004 10 : 123 46.
33. Croddy E, Krcalova S. Tularemia, biological warfare, and the battle for Stalingrad (1942-1943). Mil. Med. 2001 166 : 837 8.
34. Sjostedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann. N. Y. Acad. Sci. 2007 1105 : 1 29.
35. Tarnvik A, Berglund L. Tularaemia. Eur. Respir. J. 2003 21 : 361 73.
36. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001 285 : 2763 73.
37. Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J et al. Bichat guidelines for the clinical management of tularaemia and bioterrorism-related tularaemia. Euro Surveill. 2004 9 : E9 10.
38. Bystrom M, Bocher S, Magnusson A, Prag J, Johansson A. Tularemia in Denmark: identification of a Francisella tularensis subsp. holarctica strain by real-time PCR and high-resolution typing by multiple-locus variable-number tandem repeat analysis. J. Clin. Microbiol. 2005 43 : 5355 8.
39. Johansson A, Berglund L, Eriksson U, Goransson I, Wollin R et al. Comparative analysis of PCR versus culture for diagnosis of ulceroglandular tularemia. J. Clin. Microbiol. 2000 38 : 22 6.
40. Kantardjiev T, Padeshki P, Ivanov IN. Diagnostic approaches for oculoglandular tularemia: advantages of PCR. Br. J. Ophthalmol. 2007 91 : 1206 8.
41. Office of Communications and Public Liaison. 2006. Tularemia. National Institute of Allergy and Infectious Diseases [Accessed 1 June 2008.] Available from URL: http://www.niaid.nih.gov/factsheets/tularemia.htm.
42. Oyston PC, Quarry JE. Tularemia vaccine: past, present and future. Antonie Van Leeuwenhoek 2005 87 : 277 81.
43. Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J et al. Bichat guidelines for the clinical management of smallpox and bioterrorism-related smallpox. Euro Surveill. 2004 9 : E7 8.
44. Bray M, Buller M. Looking back at smallpox. Clin. Infect. Dis. 2004 38 : 882 9.
45. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001 285 : 1059 70.
46. Olsnes S. The history of ricin, abrin and related toxins. Toxicon. 2004 44 : 361 70.
47. Bigalke H, Rummel A. Medical aspects of toxin weapons. Toxicology 2005 214 : 210 20.
48. Griffiths GD, Phillips GJ, Holley J. Inhalation toxicology of ricin preparations: animal models, prophylactic and therapeutic approaches to protection. Inhal. Toxicol. 2007 19 : 873 87.
49. Guglielmo-Viret V, Splettstoesser W, Thullier P. An immunochromatographic test for the diagnosis of ricin inhalational poisoning. Clin. Toxicol. (Phila) 2007 45 : 505 11.
50. Wang Y, Guo L, Zhao K, Chen J, Feng J et al. Novel chimeric anti-ricin antibody C4C13 with neutralizing activity against ricin toxicity. Biotechnol. Lett. 2007 29 : 1811 16.
51. Thompson WL, Scovill JP, Pace JG. Drugs that show protective effects from ricin toxicity in in vitro protein synthesis assays. Nat. Toxins 1995 3 : 369 77.
52. Rajagopalan G, Sen MM, Singh M, Murali NS, Nath KA et al. Intranasal exposure to staphylococcal enterotoxin B elicits an acute systemic inflammatory response. Shock 2006 25 : 647 56.
53. Blazes DL, Lawler JV, Lazarus AA. When biotoxins are tools of terror. Early recognition of intentional poisoning can attenuate effects. Postgrad. Med. 2002 112 : 89 92, 95-6, 98.
54. Clarke SC. Bacteria as potential tools in bioterrorism, with an emphasis on bacterial toxins. Br. J. Biomed. Sci. 2005 62 : 40 6.
55. O'Toole T, Mair M, Inglesby TV. Shining light on 'Dark Winter'. Clin. Infect. Dis. 2002 34 : 972 83.
56. Karwa M, Bronzert P, Kvetan V. Bioterrorism and critical care. Crit. Care Clin. 2003 19 : 279 313.